Prostate Cancer Epidemiology and Genetics: 2nd Edition

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Epidemiology and Prevention".

Deadline for manuscript submissions: 15 August 2025 | Viewed by 548

Special Issue Editor


E-Mail Website
Guest Editor
1. Women’s College Research Institute, Women’s College Hospital, Toronto, ON M5S 1B2, Canada
2. Dalla Lana School of Public Health, University of Toronto, Toronto, ON M5T 3M7, Canada
3. Institute of Medical Science, University of Toronto, Toronto, ON M5S 1A8, Canada
Interests: breast cancer; ovarian cancer; BRCA1; BRCA2; cancer prevention; screening
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Prostate cancer continues to be a leading worldwide cause of male cancer morbidity and mortality. We are pleased to invite you to contribute an article to our Special Issue within the journal Cancers entitled “Prostate Cancer Epidemiology and Genetics”.

We feel that this Special Issue is a good fit for this journal as Cancers has a demonstrated commitment to the dissemination of research which explores a broad range of methods and foci related to underlying malignancy risk, and has a high Impact Factor within our field. This Special Issue aims at exploring recent developments specifically in the fields of genetics and epidemiology as they relate to prostate cancer mortality.

In this Special Issue, original research articles and reviews are welcome. Research areas may include (but are not limited to) the following:

  • The contribution of aging to the risk of prostate cancer mortality;
  • Population-level work on novel biomarkers for prostate cancer risk and progression;
  • Lifestyle factors that may impact on prostate cancer risk and progression;
  • Environmental and occupational factors that impact on prostate cancer risk and progression;
  • The contribution of specific genetic anomalies to the risk of prostate cancer mortality;
  • Clinical efforts to increase the uptake of genetic testing in patient populations;
  • Highlights from recent meetings regarding prostate cancer genetic risk.

I look forward to receiving your contributions.

Prof. Dr. Steven Narod
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • prostate cancer
  • epidemiology
  • clinical genetics
  • aging
  • population-level databases

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

18 pages, 1784 KiB  
Article
JC Polyomavirus in Prostate Cancer—Friend or Foe?
by Jacek Kiś, Dominika Sikora, Mirosław J. Jarosz and Małgorzata Polz-Dacewicz
Cancers 2025, 17(10), 1725; https://doi.org/10.3390/cancers17101725 - 21 May 2025
Viewed by 361
Abstract
Background/Objectives: Recently, many researchers have evaluated various viruses, including polyomaviruses (JCV, BKV) and EBV, as potential factors playing a role in the development and/or progression of prostate cancer (PCa), one of the most common cancers in men. Therefore, we aimed to assess [...] Read more.
Background/Objectives: Recently, many researchers have evaluated various viruses, including polyomaviruses (JCV, BKV) and EBV, as potential factors playing a role in the development and/or progression of prostate cancer (PCa), one of the most common cancers in men. Therefore, we aimed to assess the frequency of the JCPyV DNA in tissue collected from PCa patients. Methods: We detected the presence of viral DNA (PCR) in 49.6% of clinical samples, including 71.9% with single EBV infection and 28.1% with EBV/JCV co-infection. We did not detect BKV or a single JCV infection. Therefore, we compared patients with EBV mono-infection with EBV/JCV co-infected patients in the context of risk group, Gleason score, and TNM classification. Results: Our results showed differences in clinicopathological features between single EBV infection and EBV/JCV co-infection. In the group of patients with single EBV infection, most patients were classified as medium/high risk, while in the group with EBV/JCV co-infection, most patients were classified as low risk. Conclusions: Among patients with single EBV infection, a more advanced stage of cancer was observed than in EBV/JCV co-infection. Moreover, the level of anti-EBVCA and anti-EBNA antibodies as well as EBV load was higher in the case of single infection compared to EBV/JCV co-infection. Higher antibody levels were detected in more advanced tumor stages in single EBV infection. Does JCV only “reside” in prostate cells or is it a co-factor in EBV infection? In light of these studies, there is a need to clarify the role of JCV virus in the development and/or progression of prostate cancer. Full article
(This article belongs to the Special Issue Prostate Cancer Epidemiology and Genetics: 2nd Edition)
Show Figures

Figure 1

Back to TopTop